These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28939005)

  • 61. New way, new recommendation: Individualized treatment of novel antidiabetic drugs for people living with type 2 diabetes based on the cardiorenal risks.
    Xu X; Bi Y
    J Evid Based Med; 2021 Dec; 14(4):262-264. PubMed ID: 34724335
    [No Abstract]   [Full Text] [Related]  

  • 62. The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
    Czupryniak L; Dicker D; Lehmann R; Prázný M; Schernthaner G
    Cardiovasc Diabetol; 2021 Oct; 20(1):198. PubMed ID: 34598700
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Oncodiabetology II. Antidiabetics and cancer prevention].
    Bánhegyi RJ; Gazdag A; Rácz B; Szalai L; Wágner R; Fülöp N
    Orv Hetil; 2022 Oct; 163(40):1575-1584. PubMed ID: 36183266
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Precision medicine: The future in diabetes care?
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Jul; 117():12-21. PubMed ID: 27329017
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antidiabetic potential of commonly consumed legumes: a review.
    Singhal P; Kaushik G; Mathur P
    Crit Rev Food Sci Nutr; 2014; 54(5):655-72. PubMed ID: 24261538
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Perioperative handling of antidiabetic drugs].
    Wagner J; Luber V; Lock JF; Dietz UA; Lichthardt S; Matthes N; Krajinovic K; Germer CT; Knop S; Wiegering A
    Chirurg; 2018 Feb; 89(2):103-107. PubMed ID: 29260243
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Part Six: Antidiabetic Medication Benefits Beyond Glucose Lowering in Older People.
    Pogge EK; Early NK
    Sr Care Pharm; 2022 Oct; 37(10):477-487. PubMed ID: 36171669
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
    Campbell-Scherer D
    Evid Based Med; 2017 Apr; 22(2):57-58. PubMed ID: 28270434
    [No Abstract]   [Full Text] [Related]  

  • 69. Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.
    Sander D; Kearney MT
    J Neurol; 2009 Oct; 256(10):1603-19. PubMed ID: 19399381
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.
    Fuentes B; Amaro S; Alonso de Leciñana M; Arenillas JF; Ayo-Martín O; Castellanos M; Freijo M; García-Pastor A; Gomis M; Gómez Choco M; López-Cancio E; Martínez Sánchez P; Morales A; Palacio-Portilla EJ; Rodríguez-Yáñez M; Roquer J; Segura T; Serena J; Vivancos-Mora J;
    Neurologia (Engl Ed); 2021 May; 36(4):305-323. PubMed ID: 32981775
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials.
    Hinnen D; Kruger DF
    Diabetes Metab Syndr Obes; 2019; 12():447-455. PubMed ID: 31040709
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antidiabetic treatment, stroke severity and outcome.
    Magkou D; Tziomalos K
    World J Diabetes; 2014 Apr; 5(2):84-8. PubMed ID: 24748923
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antidiabetic drugs and risk of cancer.
    Tokajuk A; Krzyżanowska-Grycel E; Tokajuk A; Grycel S; Sadowska A; Car H
    Pharmacol Rep; 2015 Dec; 67(6):1240-50. PubMed ID: 26481548
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Expert consensus on stroke prevention and blood glucose management in patients with type 2 diabetes].
    Drafting Committee of the Expert Consensus on Stroke Prevention and Blood Glucose Management In Patients with Type 2 Diabetes
    Zhonghua Nei Ke Za Zhi; 2024 Jul; 63(7):649-659. PubMed ID: 38951088
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diabetes Drugs and Cardiovascular Safety.
    Bae JC
    Endocrinol Metab (Seoul); 2016 Jun; 31(2):239-44. PubMed ID: 27302713
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.
    Mohan V; Cooper ME; Matthews DR; Khunti K
    Diabetes Ther; 2019 Mar; 10(Suppl 1):1-13. PubMed ID: 30758834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cancer biology in diabetes update: Focusing on antidiabetic drugs.
    Kawakita E; Kanasaki K
    J Diabetes Investig; 2024 May; 15(5):525-540. PubMed ID: 38456597
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antidiabetic Drugs in Breast Cancer Patients.
    Garczorz W; Kosowska A; Francuz T
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254789
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimizing antidiabetic therapy: Enhancing COVID-19 outcomes for patients with type-2 diabetes.
    Kow CS; Ramachandram DS; Hasan SS
    Ann Endocrinol (Paris); 2023 Dec; 84(6):792. PubMed ID: 37903668
    [No Abstract]   [Full Text] [Related]  

  • 80. Cardiovascular impact of drugs used in the treatment of diabetes.
    Triggle CR; Ding H
    Ther Adv Chronic Dis; 2014 Nov; 5(6):245-68. PubMed ID: 25364492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.